Great Lakes Advisors LLC Takes $1.41 Million Position in Aktis Oncology $AKTS

Great Lakes Advisors LLC acquired a new stake in shares of Aktis Oncology (NASDAQ:AKTS) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 43,612 shares of the technology company’s stock, valued at approximately $1,406,000. Great Lakes Advisors LLC owned 0.08% of Aktis Oncology as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. State of Wyoming bought a new stake in Aktis Oncology during the 2nd quarter valued at $32,000. Deutsche Bank AG lifted its stake in shares of Aktis Oncology by 49.3% during the 2nd quarter. Deutsche Bank AG now owns 21,022 shares of the technology company’s stock worth $678,000 after purchasing an additional 6,942 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Aktis Oncology by 14.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 49,250 shares of the technology company’s stock worth $1,587,000 after purchasing an additional 6,349 shares during the last quarter. Finally, BlackRock Inc. boosted its position in Aktis Oncology by 7.9% during the second quarter. BlackRock Inc. now owns 2,278,358 shares of the technology company’s stock valued at $73,431,000 after purchasing an additional 166,231 shares in the last quarter. Institutional investors own 28.84% of the company’s stock.

Wall Street Analysts Forecast Growth

AKTS has been the subject of a number of recent research reports. Wall Street Zen downgraded shares of Aktis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. Weiss Ratings raised shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Raymond James Financial assumed coverage on shares of Aktis Oncology in a research note on Monday, June 15th. They set a “strong-buy” rating and a $40.00 price objective for the company. BMO Capital Markets assumed coverage on shares of Aktis Oncology in a research report on Tuesday. They set an “outperform” rating and a $37.00 target price for the company. Finally, William Blair began coverage on shares of Aktis Oncology in a research note on Wednesday, April 29th. They issued an “outperform” rating for the company. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $35.00.

Insiders Place Their Bets

In other news, Director Ken Herrmann sold 4,856 shares of the business’s stock in a transaction on Monday, July 20th. The shares were sold at an average price of $24.56, for a total transaction of $119,263.36. Following the sale, the director directly owned 3,506 shares of the company’s stock, valued at $86,107.36. The trade was a 58.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 3.30% of the company’s stock.

Aktis Oncology Stock Performance

Aktis Oncology stock opened at $24.07 on Friday. The stock has a 50-day moving average of $25.49 and a two-hundred day moving average of $21.29. Aktis Oncology has a one year low of $14.72 and a one year high of $34.19. The stock has a market cap of $1.29 billion and a PE ratio of -29.35.

Aktis Oncology (NASDAQ:AKTS) last issued its quarterly earnings results on Thursday, August 13th. The technology company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The business had revenue of $3.38 million during the quarter, compared to analyst estimates of $2.70 million. As a group, sell-side analysts predict that Aktis Oncology will post -1.8 EPS for the current fiscal year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.